help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Molecular Endocrinology, doi:10.1210/me.2006-0304
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carnevale, R. P.
Right arrow Articles by Elizalde, P. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carnevale, R. P.
Right arrow Articles by Elizalde, P. V.
Molecular Endocrinology 21 (6): 1335-1358
Copyright © 2007 by The Endocrine Society

Progestin Effects on Breast Cancer Cell Proliferation, Proteases Activation, and in Vivo Development of Metastatic Phenotype All Depend on Progesterone Receptor Capacity to Activate Cytoplasmic Signaling Pathways

Romina P. Carnevale, Cecilia J. Proietti, Mariana Salatino, Alejandro Urtreger, Guillermo Peluffo, Dean P. Edwards, Viroj Boonyaratanakornkit, Eduardo H. Charreau, Elisa Bal de Kier Joffé, Roxana Schillaci and Patricia V. Elizalde

Instituto de Biología y Medicina Experimental (IBYME) (R.P.C., C.J.P., M.S., E.H.C., R.S., P.V.E.), Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires C1428ADN, Argentina; Research Area (A.U., G.P., E.B.d.K.J.), Institute of Oncology Angel H. Roffo, University of Buenos Aires, C1417DTB Buenos Aires, Argentina; and Department of Molecular and Cellular Biology and Pathology (D.P.E., V.B.), Baylor College of Medicine, Houston, Texas 77030

Address all correspondence and requests for reprints to: Patricia V. Elizalde, Ph.D., Laboratory of Molecular Mechanisms of Carcinogenesis, Instituto de Biología y Medicina Experimental (IBYME), Vuelta de Obligado 2490, Buenos Aires 1428, Argentina. E-mail: elizalde{at}dna.uba.ar.

Accumulating evidence indicates that progestins are involved in controlling mammary gland tumorigenesis. Here, we assessed the molecular mechanisms of progestin action in breast cancer models with different phenotypes. We examined C4HD cells, an estrogen (ER) and progesterone (PR) receptor-positive murine breast cancer model in which progestins exert sustained proliferative response, the LM3 murine metastatic mammary tumor cell line, which lacks PR and ER expression, and human PR null T47D-Y breast cancer cells. In addition to acting as a transcription factor, PR can also function as an activator of signaling pathways. To explore which of these two functions were involved in progestin responses, reconstitution experiments in the PR-negative models were performed with wild-type PR-B, with a DNA binding mutant C587A-PR, and with mutant PR-BmPro, which lacks the ability to activate cytoplasm signaling pathways. We found that in a cell context either ER-positive or -negative, progestins induced cell growth and modulation of matrix metalloproteinases-9 (MMP-9) and -2 (MMP-2), and urokinase-type plasminogen activator (uPA) activities, via MAPK and phosphatidylinositol 3-kinase/Akt pathways, in cells expressing wild-type PR-B or DNA binding mutant C587A-PR. In contrast, in cells expressing mutant PR-BmPro, progestins did not induce growth. We also found that unliganded PR expression conferred breast cancer cells an in vitro less proliferative phenotype, as compared with cells lacking PR expression. Modulation of this behavior occurred when PR was functioning either as transcription factor or as signaling activator. Finally, we for the first time demonstrated that progestins favor development of breast tumor metastasis via PR function as activator of signaling pathways. Our present findings provide mechanistic support to the design of a novel therapeutic intervention in PR-positive breast tumors involving blockage of PR capacity to activate cytoplasmic signaling.

NURSA Molecule Pages Link:

Nuclear Receptors:   PR
Ligands:   Mifepristone



This article has been cited by other articles:


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
M. E. Schmidt, K. Steindorf, E. Mutschelknauss, T. Slanger, S. Kropp, N. Obi, D. Flesch-Janys, and J. Chang-Claude
Physical Activity and Postmenopausal Breast Cancer: Effect Modification by Breast Cancer Subtypes and Effective Periods in Life
Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3402 - 3410.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Gastrointest. Liver Physiol.Home page
S. Glaser, S. DeMorrow, H. Francis, Y. Ueno, E. Gaudio, S. Vaculin, J. Venter, A. Franchitto, P. Onori, B. Vaculin, et al.
Progesterone stimulates the proliferation of female and male cholangiocytes via autocrine/paracrine mechanisms
Am J Physiol Gastrointest Liver Physiol, July 1, 2008; 295(1): G124 - G136.
[Abstract] [Full Text] [PDF]


Home page
Mol Hum ReprodHome page
X.-D. Fu, M. Flamini, A. M. Sanchez, L. Goglia, M. S. Giretti, A. R. Genazzani, and T. Simoncini
Progestogens regulate endothelial actin cytoskeleton and cell movement via the actin-binding protein moesin
Mol. Hum. Reprod., April 1, 2008; 14(4): 225 - 234.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
S. R. Hammes and E. R. Levin
Extranuclear Steroid Receptors: Nature and Actions
Endocr. Rev., December 1, 2007; 28(7): 726 - 741.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2007 by The Endocrine Society